Ipsen ((GB:0MH6)), Ipsen (($CC:IPN.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a recent update, Ipsen has announced the recruitment phase for its Phase II clinical study titled A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants. The study aims to assess the efficacy and safety of IPN10200, a potential long-lasting treatment for Cervical Dystonia, a condition causing neck pain and stiffness.
The intervention being tested is IPN10200, a biological treatment administered via intramuscular injection, designed to provide longer-lasting relief compared to current treatments. The study also includes a placebo group for comparison.
This interventional study employs a randomized, parallel assignment model with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is to evaluate the treatment’s effectiveness.
The study began on June 30, 2025, with primary completion and estimated completion dates yet to be announced. The last update was submitted on August 7, 2025, indicating ongoing recruitment efforts.
For investors, the successful development of IPN10200 could enhance Ipsen’s market position, potentially boosting stock performance. The study’s progress will be closely watched, given the competitive landscape in neurological treatments.
The study is currently ongoing, with further details available on the ClinicalTrials portal.